| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -204,121 | -182,956 |
| Depreciation and amortization expense | 13,171 | 8,678 |
| Amortization of debt issuance costs | 1,414 | 970 |
| Provision for expected credit losses | 6,745 | 3,577 |
| Operating lease and other impairment charges | 6,697 | 6,697 |
| Amortization of discount or (accretion of premium) on short-term investments | 2,083 | 1,780 |
| Loss from equity method investments | -9,641 | -6,917 |
| Stock-based compensation expense | 72,271 | 51,130 |
| Loss on extinguishment of debt | 0 | 0 |
| Acquired in-process research and development expenses | 75,217 | 75,217 |
| Other | 1,041 | 424 |
| Accounts receivable, net | 14,798 | 13,516 |
| Inventories | -17,252 | -12,058 |
| Prepaid and other current assets | 12,140 | 2,348 |
| Other long-term assets | -3,585 | -3,524 |
| Accounts payable and accrued expenses | -3,591 | 5,739 |
| Employee-related liabilities | 197 | -12,649 |
| Deferred revenue | -4,102 | -2,710 |
| Operating leases and other current liabilities | 9,017 | 8,403 |
| Other long-term liabilities | 5,077 | 4,851 |
| Net cash provided by (used in) operating activities | -19,510 | -27,774 |
| Purchases of short-term investments | 56,004 | 26,496 |
| Proceeds from maturities and redemptions of short-term investments | 200,583 | 146,447 |
| Purchases of property and equipment | 13,263 | 9,171 |
| Acquisition of in-process research and development | 43,464 | 43,464 |
| Net cash provided by (used in) investing activities | 87,852 | 67,316 |
| Proceeds from issuance of convertible senior notes due 2029, net of 9,400 debt issuance costs | 0 | 0 |
| Repurchase of 246,740 principal amount of convertible senior notes due 2025 | 0 | 0 |
| Principal payments on convertible senior notes due 2025 | 40,760 | 40,760 |
| Payment for capped call transactions related to convertible senior notes due 2029 | 0 | 0 |
| Repurchase and retirement of common stock | 0 | 0 |
| Cash used to settle withholding taxes on vested restricted stock, net of proceeds from issuance of common stock under company stock plans | 5,211 | 3,641 |
| Other financing activities | 0 | 0 |
| Net cash provided by (used in) financing activities | -45,971 | -44,401 |
| Effect of foreign exchange rate changes on cash | 342 | -263 |
| Net increase (decrease) in cash and cash equivalents | 22,713 | -5,122 |
| Cash and cash equivalents at beginning of period | 69,234 | - |
| Cash and cash equivalents at end of period | 91,947 | - |
TANDEM DIABETES CARE INC (TNDM)
TANDEM DIABETES CARE INC (TNDM)